FLR Form 144 shows $4.0M planned insider sale of common stock

Rhea-AI Filing Summary

Fluor Corporation has a planned sale of 71,200 shares of its common stock under Rule 144. The shares are to be sold through Merrill Lynch on the NYSE, with an aggregate market value of $4,014,800 based on the figures provided. The filing states that there were 161,182,507 shares outstanding of this class at the time of the notice, giving context for the size of the transaction.

The shares being sold were acquired as restricted stock equity awards from Fluor Corporation on three dates: 50,608 shares on 03/06/2023, 18,323 shares on 12/23/2023, and 2,269 shares on 03/06/2024, with the payment described as equity awards rather than cash purchases. The notice also includes a representation that the seller does not know of undisclosed material adverse information about Fluor’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 13355 Noel Road Suite Suite 700 Dallas TX 75240	71200	4014800	161182507	11/17/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	03/06/2023	RESTRICTED STOCK	FLUOR CORPORATION			50608	03/06/2023	EQUITY AWARD
COMMON	12/23/2023	RESTRICTED STOCK	FLUOR CORPORATION			18323	12/23/2023	EQUITY AWARD
COMMON	03/06/2024	RESTRICTED STOCK	FLUOR CORPORATION			2269	03/06/2024	EQUITY AWARD

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for FLR disclose about share sales?

The Form 144 for Fluor Corporation (FLR) discloses an intended sale of 71,200 shares of Fluor common stock under Rule 144, with an indicated aggregate market value of $4,014,800. The sale is planned to be executed through Merrill Lynch on the NYSE around 11/17/2025.

How large is the planned FLR share sale compared to shares outstanding?

The filing reports that 161,182,507 shares of Fluor common stock were outstanding. The planned Rule 144 sale covers 71,200 shares, which is a small portion of the total shares outstanding.

How were the Fluor (FLR) shares being sold under Rule 144 originally acquired?

The shares being sold were acquired as restricted stock equity awards from Fluor Corporation. The filing lists 50,608 shares granted on 03/06/2023, 18,323 shares on 12/23/2023, and 2,269 shares on 03/06/2024, all described as equity awards rather than cash purchases.

Which broker and exchange are used for the planned FLR share sale?

The planned sale of 71,200 Fluor Corporation common shares is listed as being executed through Merrill Lynch, with the securities to be sold on the NYSE, according to the Rule 144 filing.

What price information is implied in the Fluor Form 144 filing?

The filing shows an aggregate market value of $4,014,800 for 71,200 shares of Fluor common stock to be sold. This figure reflects the value used for the notice but does not itself set the actual future sale price.

Does the Form 144 for FLR include any representation about undisclosed information?

Yes. The notice includes a representation that the person for whose account the securities are to be sold does not know any material adverse information about Fluor’s current or prospective operations that has not been publicly disclosed.